Chimerix Announces Upcoming Presentations at the Society for Neuro-Oncology Annual Meeting 2021
Details for the late-breaking plenary oral presentation are as follows:
Title: Clinical efficacy of ONC201 in recurrent H3 K27M-mutant diffuse midline glioma patients
Abstract Number: LTBK-05
Date and Time: November 20, 2021 from 9:37 a.m. –
Presenter: Isabel Arrillaga-Romany, M.D., Ph. D.,
Details for additional oral and poster presentations are as follows:
Title: Single agent activity of ONC201 in non-midline H3 K27M-mutant diffuse gliomas
Abstract Number: CTNI-27
Date and Time: November 19, 2021 from 7:30 p.m. -
Presenter: Yazmin Odia, M.D., M.S., FAAN,
Title: Safety of ONC201 administered two consecutive days per week in pediatric H3 K27M-mutant glioma patients
Abstract Number: CTNI-36
Date and Time: November 19, 2021 from 7:30 p.m. -
Presenter: Sharon L.
Title: Dual metabolic reprogramming by ONC201/TIC10 and 2-Deoxyglucose has a strong antiproliferative effect on medulloblastoma cells
Abstract Number: EXTH-68
Date and Time: November 19, 2021 from 7:30 p.m. -
Presenter: Georg Karpel-Massler, M.D., Ph.D.,
Title: Induction of Synthetic Lethality by Activation of Mitochondrial ClpP and Inhibition of HDAC1/2 in Glioblastoma
Abstract Number: TAMI-17
Date and Time: November 19, 2021 from 7:30 p.m. -
Presenter: Trang T. Nguyen, Ph.D.,
Title: Harnessing Cellular Stress for Immune Targeting of DIPGs
Abstract Number: EXTH-30
Date and Time: November 19, 2021 from 7:30 p.m. -
Presenter: Donghang Cheng, Ph.D.,
Title: Serial plasma and CSF cell-free tumor DNA (cf-tDNA) tracking in diffuse midline glioma patients undergoing treatment with ONC201
Abstract Number: BIOM-28
Date and Time: November 21, 2021 from 11:35 a.m. –
Presenter: Evan Cantor, M.D., J.D.,
About Chimerix
CONTACT:
Investor Relations:
919-972-7115
ir@chimerix.com
Will O’Connor
Stern Investor Relations
212-362-1200
will@sternir.com
Source: Chimerix, Inc.